🔎 Trials Near Me

Home › Obesity › NCT07321886

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

RecruitingPhase 3

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Have Body Mass Index (BMI) at screening of the following:

  * 30 kilogram per square meter (kg/m2) OR
  * 27 kg/m2 with at least one of the following weight-related health conditions at screening:

    * high blood pressure
    * dyslipidemia
    * obstructive sleep apnea, or
    * heart disease
* Have a stable body weight (\<5% body weight change) for 90 days prior to screening.
* Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight

Exclusion Criteria:

* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
* Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
* Have type 1 diabetes or type 2 diabetes
* Have had within 90 days prior to screening:

  * heart attack
  * stroke
  * coronary artery revascularization
  * unstable angina, or
  * hospitalization due to congestive heart failure
* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
* Have taken medications or alternative remedies intended for weight loss within 90 days of screening

About the study

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.

Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.

What is being tested

Sponsor: Eli Lilly and Company · Participants: 1,980 · Started: Feb 6, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07321886

Locations in the U.S.

AlabamaMFA Clinical Research, Tuscaloosa
ArizonaHeadlands Research - Scottsdale, Scottsdale
CaliforniaNeighborhood Healthcare Institute of Health, Escondido
Ark Clinical Research - Fountain Valley, Fountain Valley
Desert Oasis Healthcare Medical Group, Palm Springs
Peninsula Research Associates, Rolling Hills Estates
Care Access - Sacramento, Sacramento
Southern California Clinical Research, Santa Ana
University Clinical Investigators, Inc., Tustin
ConnecticutChase Medical Research, LLC, Waterbury
FloridaJEM Research Institute, Atlantis
BioMed Research & Medical Center, Miami
Adult Medicine of Lake County, Inc., Mt. Dora
American Research Centers of Florida, Pembroke Pines
AHF Pensacola, Pensacola
IMA Clinical Research St. Petersburg, St. Petersburg
GeorgiaTeak Research Consults - Dunwoody, Dunwoody
Teak Research Consults, Lawrenceville
Clinical Research Atlanta, Stockbridge
HawaiiEast-West Medical Research Institute, Honolulu
IowaIowa Diabetes and Endocrinology Research Center, West Des Moines
KansasCotton O'Neil Clinical Research Center, Topeka
LouisianaCare Access - Lake Charles (Bayou Pines), Lake Charles
MarylandMedStar Good Samaritan Hospital, Baltimore
MedStar Health Research Institute (MedStar Physician Based Research Network), Hyattsville
MassachusettsCare Access - Quincy, Quincy
MichiganArcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
NevadaAMR Clinical, Las Vegas
New JerseyIMA Clinical Research Warren, Warren Township
New MexicoAlbuquerque Clinical Trials, Inc., Albuquerque
New YorkRochester Clinical Research, LLC, Rochester
North CarolinaMonroe Biomedical Research, Monroe
PennsylvaniaPreferred Primary Care Physicians, Uniontown
South CarolinaTribe Clinical Research, LLC, Greenville
Accellacare - Mt Pleasant, Mt. Pleasant
TennesseeAMR Clinical, Nashville
TexasThe University of Texas Health Science Center at Houston, Bellaire
UT Southwestern Medical Center, Dallas
Velocity Clinical Research, Dallas, Dallas
IMA Clinical Research San Antonio, San Antonio
VirginiaAMR Clinical, Norfolk

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.